Sun Pharmaceutical Industries

Sun Pharma forecasts high single-digit revenue growth for FY27 after an 11.9% increase in FY26 revenue. The company aims to expand its innovative portfolio amid regulatory challenges and compliance issues, while also focusing on acquisitions and new product launches in the obesity-drug market.

Sun Pharma Q4 results 2026: Profit jumped 26% YoY to ₹ 2,714 crore. Total revenue from operations for the quarter under review rose 12.8% YoY to ₹ 14,611.79 crore. Sun Pharma's board recommended a final dividend of ₹ 5 per share of ₹ l each.

The Nifty Pharma index has surged nearly 11% over the past month, significantly outperforming the Nifty 50, which declined 3.6% during the same period. On a year-to-date (YTD) basis, the Nifty Pharma index has gained 9.4%, while the benchmark Nifty 50 has fallen by an equal margin.

Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 19 May 2026 - Sun Pharmaceutical Industries, BSE and PB Fintech shares.

Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 12 May 2026 - Sun Pharmaceutical Industries, Fortis Healthcare and Grasim Industries.

Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals.

Sun Pharma's $11.75 billion buyout of Organon signifies a strategic shift from focusing on the US generics market to seeking geographic diversification as an antidote to tariff volatility and pricing pressures there. Read how the M&A helps Sun Pharma and why its shares jumped nearly 7% Monday.

Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — Bharat Electronics, Sun Pharmaceutical Industries, and NTPC.